Acronym

Meaning

ABG

Arterial Blood Gas

AIHA

Autoimmune Hemolytic Anemia

AE

Adverse Event

Alb

Albumin

ALC

Absolute Lymphocyte Count

ALL

Acute Lymphoblastic Leukemia

AML

Acute Myeloid Leukemia

ANC

Absolute Neutrophil Count

ASCO

American Society of Clinical Oncology

ASH

American Society of Hematology

B2M

Beta2-Microglobulin

BCL-2

B-cell lymphoma 2

BCR

B-cell Receptor

BM

Bone Marrow

BMBx

Bone Marrow Biopsy

BMT

Bone Marrow Transplant

BR

Bendamustine and Rituximab

BTK

Bruton’s Tyrosine Kinase

BUN

Blood Urea Nitrogen

Ca

Calcium

CAM

Complementary and Alternative Medicine

CAR-T

Chimeric Antigen Receptor T-cell

CBC

Complete Blood Count

CD

Cluster of Differentiation

CIT

Chemo immuno Therapy

CK

Complex Karotype

Cl

Chlorine

CLL

Chronic Lymphocytic Leukemia

CML

Chronic Myeloid Leukemia

CO2

Carbon Dioxide

CP

Convalescent Plasma

Cr

Creatinine

CR

Complete Response

CRS

Cytokine Release Syndrome

Del (17p)

17p Deletion

DFS

Disease Free Survival

DLBCL

Diffuse Large B-Cell Lymphoma

DoR

Duration of Response

Dx

Diagnosis

Dz

Disease

EHA

European Hematology Association

EOT

End of Treatment

FCR

Fludarabine, Cyclophosphamide, Rituximab

FISH

Fluorescence In Situ Hybridization

GVHD

Graft Versus Host Disease

HCT

Hematocrit

HDMP

High dose methyl-prednisolone

HGB

Hemoglobin level

HLA

Human Leukocyte Antigen

HSCT

Hematopoietic Stem Cell Transplant

Hx

History

IAHA

Idiopathic Autoimmune Hemolytic Anemia

Ibr

Ibrutinib

IRC

Independent Review Committee

ITP

Idiopathic (or Immune) Thrombocytopenic Purpura

IwCLL

International Workshop on CLL

K

Potassium

LD

Longest Diameter

LDH

Lactate Dehydrogenase

LDT

Lymphocyte Doubling Time

LN

Lymph Node

MAB

Monoclonal Antibodies

MBL

Monoclonal B-Cell Lymphocytosis

MCH

Mean Corpuscular Hemoglobin

MCHC

Mean Corpuscular Hemoglobin Concentration

MCV

Mean Corpuscular Volume

MDS

Myelodysplastic Syndromes

MPV

Mean Platelet Volume

MRD

Minimal or Measurable Residual Disease

Na

Sodium

NGS

Next Generation Sequencing

O2

Oxygen

ORR

Overall Response Rate

OS

Overall Survival

PB

Peripheral Blood

PCR

Polymerase Chain Reaction

PD

Progressive Disease

PFS

Progression Free Survival

PI3K

Phosphoinositide 3-kinase

PLT

Platelets

PR

Partial Response/Partial Remission

Pt

Patient

R

Rituximab

R/R

Relapsed/Refractory

RBC

Red Blood Cell

RCHOP

Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, Prednisone

RDW

Red cell Distribution Width

RT

Richter’s Transformation

SCT

Stem Cell Transplant

SGPT

Serum Glutamic Pyruvic Transaminase

SL

Synthetic Lethality

SLL

Small Lymphocytic Lymphoma

TB4T

Test Before Treat

TBI

Total Body Irradiation

TKI

Tyrosine Kinase Inhibitors

TLS

Tumor Lysis Syndrome

TN

Treatment Naive

TTNT

Time to Next Treatment

TTP

Time to Progression

TTT

Time to Treat

Tx

Treatment

URI

Upper Respiratory Infection

VenR

Venetoclax-Rituximab

Vx

Venetoclax

W&W

Watch and Wait

WBC

White Blood Cells

WM

Waldenstrom’s Macroglobulinemia

Updated: February 4, 2021